Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Gal Omry"'
Autor:
Gal Omry-Orbach
Publikováno v:
Rambam Maimonides Medical Journal, Vol 7, Iss 1, p e0003 (2016)
Thyroid cancer is an increasingly common malignancy, with a rapidly rising prevalence worldwide. The social and economic ramifications of the increase in thyroid cancer are multiple. Though mortality from thyroid cancer is low, and most patients will
Externí odkaz:
https://doaj.org/article/d05c0f7bf0a448bbb66dfdff2849807e
Publikováno v:
Clinical Endocrinology. 76:582-585
Summary Context Thyroid cancer survivors represent a unique population in which the potential long-term effects of brief periods of intentional thyroid hormone withdrawal and/or prolonged periods of iatrogenic hyperthyroidism on body weight and body
Publikováno v:
The Israel Medical Association journal : IMAJ. 16(2)
To prevent the unwarranted effects of post-thyroidectomy hypothyroidism prior to radiodine (RAI) ablation, patients with well-differentiated thyroid cancer can currently undergo this treatment while in a euthyroid state. This is achieved with the use
Publikováno v:
Clinical endocrinology. 76(4)
Thyroid cancer survivors represent a unique population in which the potential long-term effects of brief periods of intentional thyroid hormone withdrawal and/or prolonged periods of iatrogenic hyperthyroidism on body weight and body mass were evalua
Autor:
Jatin P. Shah, Gal Omry, Ashok R. Shaha, James A. Fagin, Rebecca Leboeuf, R. Michael Tuttle, Mithat Gonen, Hernán Tala, Matvey Brokhin, Ronald Ghossein
A risk-adapted approach to management of thyroid cancer requires risk estimates that change over time based on response to therapy and the course of the disease. The objective of this study was to validate the American Thyroid Association (ATA) risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16fb05600febaa4d2ff171fe01756255
https://europepmc.org/articles/PMC4845674/
https://europepmc.org/articles/PMC4845674/
Autor:
Gal Omry, Matvey Brokhin, Norma Lopez, Steve Larson, Rebecca Leboeuf, Ravinder K. Grewal, Shaye M. Minkowitz, R. Michael Tuttle
Publikováno v:
Thyroid : official journal of the American Thyroid Association. 20(3)
In December 2007, the USFDA approved recombinant human thyroid stimulating hormone (rhTSH) for radioiodine remnant ablation after total thyroidectomy in patients with well-differentiated thyroid cancer without evidence of metastatic disease. Because
Autor:
Gal Omry, Carol J. Levy
Publikováno v:
A Case-Based Guide to Clinical Endocrinology ISBN: 9781588298157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf0d0e9f453a953d855aab744c569275
https://doi.org/10.1007/978-1-60327-103-5_34
https://doi.org/10.1007/978-1-60327-103-5_34
Autor:
R. Michael Tuttle, Andrew J. Martorella, Matvey Brokhin, Richard J. Robbins, Steven M. Larson, Gal Omry, Ravinder K. Grewal, Martin Fleisher
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 49(5)
Recent studies have confirmed that radioactive iodine therapy after recombinant human TSH (rhTSH) stimulation effectively ablates the normal thyroid remnant. However, no published study has determined the effectiveness of rhTSH preparations on the im
Autor:
R. Michael Tuttle, Hernan Tala, Jatin Shah, Rebecca Leboeuf, Ronald Ghossein, Mithat Gonen, Matvey Brokhin, Gal Omry, James A. Fagin, Ashok Shaha
Publikováno v:
Thyroid; Dec2010, Vol. 20 Issue 12, p1341-1349, 9p